In the BioHarmony Drug Report Database

"Preview" Icon

Ocrelizumab

Ocrevus (ocrelizumab) is an antibody pharmaceutical. Ocrelizumab was first approved as Ocrevus on 2017-03-28. It is used to treat multiple sclerosis in the USA. It has been approved in Europe to treat multiple sclerosis. The pharmaceutical is active against B-lymphocyte antigen CD20.

 

Trade Name

 

Ocrevus
 

Common Name

 

ocrelizumab
 

ChEMBL ID

 

CHEMBL2108041
 

Indication

 

multiple sclerosis
 

Drug Class

 

Monoclonal antibodies: humanized, immunomodulating

Image (chem structure or protein)

Ocrelizumab structure rendering